Dr. Brufsky on Choosing When to do a Multiparameter Genomic Assay
March 12th 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for a patient with early-stage breast cancer.
Read More
Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer
February 2nd 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the COLET trial combining cobimetinib (Cotellic) and paclitaxel (Abraxane) as a treatment for patients with triple-negative breast cancer (TNBC).
Read More
Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC
January 4th 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.
Read More
Dr. Brufsky on Anastrozole Versus Tamoxifen in DCIS
June 3rd 2015Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).
Read More
Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer
August 21st 2014Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.
Read More
Dr. Brufsky on Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer
July 11th 2014Adam M. Brufsky, MD, PhD, discusses the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.
Read More